Expand SPRY Menu
SPRY MENU

SPRY Latest Press Releases

-- July 9, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY PRNewswire 5:37 PM

-- July 7, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY Globe Newswire 5:38 PM
ARS Pharmaceuticals Announces CEO Succession Globe Newswire 4:30 PM

-- July 6, 2026 --

ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 2:00 PM

-- July 1, 2026 --

SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud Business Wire 10:07 AM

-- June 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY Globe Newswire 4:45 PM

-- June 29, 2026 --

ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) PRNewswire 1:26 PM

-- June 28, 2026 --

SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm Business Wire 11:54 AM

-- June 24, 2026 --

ARS Pharmaceuticals Provides Commercial and Financial Updates Globe Newswire 4:05 PM

-- June 4, 2026 --

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies Globe Newswire 8:00 AM

-- May 15, 2026 --

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Globe Newswire 6:00 AM

-- May 13, 2026 --

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President Globe Newswire 8:00 AM

-- May 7, 2026 --

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- April 15, 2026 --

neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) Globe Newswire 6:05 AM

-- March 27, 2026 --

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label Globe Newswire 8:00 AM

-- March 9, 2026 --

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization Globe Newswire 6:00 AM

-- February 23, 2026 --

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes